Related Experiment Video
Updated: Jul 6, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Can carboplatin replace cisplatin for intraperitoneal use?
1Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka-City, Saitama, Japan. fujiwara@saitama-med.ac.jp
Abstract:
Intraperitoneal (IP) chemotherapy is theoretically a feasible route for treating ovarian cancer. It is possible to expose tumor tissue disseminated peritoneal surface to extremely high concentration of anticancer agents. Three large-scale, randomized trials conducted in the US have demonstrated a significant improvement of progression survival and/or overall survival in IP chemotherapy arm over intravenous arm. Despite these favorable results, IP chemotherapy has not been accepted as standard care. One of the reasons for this is the use of cisplatin, which has been replaced by the less toxic platinum agent, carboplatin, when administered intravenously. In this review article, we discuss why IP chemotherapy using carboplatin has been ignored and its future potential.
More Related Videos
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists